TL;DR: Pharmaceutical sales rep OTE in Europe typically runs €35,000–€75,000 for confirmed reps and €50,000–€90,000+ for senior specialists, depending on market and therapeutic area. Unlike SaaS sales roles — where OTE often splits close to 50/50 — pharma comp is base-heavy: usually 70–85% fixed salary with a 15–30% variable component tied to territory attainment and activity KPIs, not raw deal-closing.
Most of what ranks for “pharmaceutical sales rep salary” today is aimed at job seekers — Glassdoor, Indeed, ZipRecruiter. If you’re the one setting pay, not searching for a job, that data is only half the picture: it tells you what people earn, not how the pay is structured or whether your plan design matches the market. This guide is written for the employer side: what European pharma reps actually earn, how base and variable break down, how to know if your OTE is competitive — and how to actually run the plan once you’ve set it.
Why pharma OTE looks different from SaaS OTE
In B2B SaaS, on-target earnings often split evenly between base and commission — reps are paid to close. Pharma reps don’t close; they influence prescribing behaviour over time, working within strict promotional regulations (see ABPI’s overview of pharma sales ). That changes the whole shape of the plan:
- Base salary carries more weight — typically 70–85% of total OTE, versus 50–65% for a comparable SaaS AE.
- The variable component is smaller but more complex — usually a weighted KPI basket (territory attainment adjusted for market potential, call/coverage activity, and strategic or launch-related goals) rather than a straight commission rate.
- Company car, expenses, and benefits are a meaningful part of total reward in most European markets, on top of the cash figures below.
If you’re benchmarking against generic sales-comp data, you’ll consistently read pharma OTE as “too low” — it isn’t; it’s differently structured.
OTE benchmarks by market
Figures are annual gross OTE (base + typical variable), compiled from public salary data, recruiter salary guides, and government labour data across markets. Treat these as directional — actual pay varies by therapeutic area (oncology and rare disease consistently pay above general primary care), company size, and whether the role covers a hospital or retail/primary-care channel.
| Entry (0–2 yrs) | Confirmed (3–7 yrs) | Senior / specialist (8+ yrs) | Typical variable share | |
|---|---|---|---|---|
| UK | £30,000–£38,000 | £45,000–£60,000 | £60,000–£86,000 | ~20–25% |
| Germany | €45,000–€55,000 | €65,000–€90,000 | €90,000–€120,000+ | ~20–25% |
| France | €28,000–€32,000 | €35,000–€50,000 | €50,000–€65,000 | ~15–30% |
| Spain | €22,000–€30,000 | €35,000–€55,000 | €55,000–€80,000+ | ~20–30% |
London and other high-cost metros typically run 15–25% above national UK averages. Hospital-channel and specialist (oncology, immunology, rare disease) reps consistently sit at the top of each range; retail/primary-care generalist roles sit at the bottom. See Michael Page’s fiche métier for délégué médical and HelloWork’s délégué pharmaceutique data for the France figures specifically.
What actually moves pharma OTE
Therapeutic area. Specialist and hospital-channel reps (oncology, immunology, biosimilars) command a premium over primary-care generalist roles — often 20–40% higher OTE for a comparable seniority level, reflecting the more technical sell and smaller, higher-value prescriber base.
Channel. Reps calling on hospitals and specialists are paid more than those covering community pharmacies and GPs, across every market we looked at.
Company size and origin. Large multinationals generally pay a premium over mid-size and generic manufacturers, particularly on the variable side and in benefits (car policy, pension).
Plan design, not just market rate. Two companies paying the same OTE can produce very different outcomes if one measures raw territory sales and the other adjusts quotas for market potential (prescriber density, patient population, historical prescribing). The second is fairer to reps in lower-potential territories — and retains them longer. We cover this in detail in how to design a field-force incentive plan in pharma.
Setting a competitive OTE: a quick framework
- Anchor to channel and therapeutic area first, market average second. A generic national average will underpay your specialist hospital reps and overpay your retail generalists.
- Check your base/variable split against the category norm. If you’re running a 50/50 split like a SaaS plan, you’re likely over-indexing on variable pay for a role that doesn’t close deals — and creating compliance risk in how that variable is earned.
- Adjust quotas for market potential, not flat targets. Reps in high-potential territories will out-earn reps in low-potential ones under a flat model regardless of effort — a genuine retention risk in low-potential regions.
- Model scenarios before you commit. Remu, Remuner’s AI compensation manager, can simulate how a proposed OTE and KPI basket would have paid out against last year’s territory data — so you see the real cost and distribution before the plan goes live, not after Q1.
How Remuner handles pharma commission
Setting a competitive OTE is only half the problem — actually calculating and paying it, cycle after cycle, is where most pharma teams get stuck with an inherited spreadsheet. Remuner is built to run the plan once you’ve designed it:
- Weighted KPI baskets, automated. Blend potential-adjusted territory attainment, call/coverage activity, and strategic or launch goals into a single incentive score — with weights you control and can retune each cycle as products move through their lifecycle.
- Territory quotas adjusted for market potential, not flat targets, so a rep in a dense metro isn’t compared unfairly to one covering a rural region.
- Native reconciliation across Veeva, IQVIA, and your ERP, so the sales, activity, and prescribing data behind every payout comes from one consistent model instead of three spreadsheets that disagree.
- A compliance-grade audit trail — every plan version, weight change, and approval is recorded, so when compliance or an auditor asks why a rep was paid a given amount in Q2, there’s a five-minute answer instead of a scramble.
- Real-time visibility for reps, so the field can see their KPI attainment as it happens rather than waiting for a quarterly reconciliation.
Customers like Alfasigma have used Remuner to move field-force incentive calculation off a legacy spreadsheet entirely. For the full design walkthrough — territory quotas, KPI basket weighting, and the compliance angle.
The Bottom Line
European pharma sales rep OTE runs from roughly €28,000 (entry-level France) to €120,000+ (senior specialist Germany), but the number that matters most isn’t the average — it’s whether your base/variable split and quota design match how pharma reps are actually rewarded to perform: influence and activity, not raw deal volume. Get the structure right, and the specific figure becomes a market-anchoring exercise rather than a guess. Get the calculation and audit trail right, and it stops being a quarterly fire drill too.
Frequently asked questions
What is a good OTE for a pharmaceutical sales rep in Europe?
It depends heavily on market, channel, and therapeutic area — but for a confirmed (3–7 year) generalist rep, €35,000–€60,000 total OTE is typical across the UK, Germany, France, and Spain, rising to €80,000–€120,000+ for senior specialists in hospital or rare-disease channels.
Why is pharma sales compensation more base-heavy than SaaS?
Because pharma reps influence prescribing behaviour over time rather than closing transactional deals, and promotional regulations constrain how aggressively variable pay can be tied to sales outcomes. Base salary typically makes up 70–85% of OTE, versus roughly 50–65% for a comparable SaaS account executive.
Should pharma sales quotas be the same for every territory?
No. Flat quotas reward territory potential rather than rep effort — a rep in a high-prescriber metro will out-earn an equally effective rep in a rural territory. Adjusting quotas for market potential (prescriber density, patient population, historical prescribing) is fairer and improves retention in lower-potential regions.
Do pharma sales reps get commission on individual sales?
Rarely in the direct, per-deal sense a SaaS rep would recognise. Most European pharma incentive plans pay against a weighted KPI basket — territory attainment adjusted for market potential, plus activity and strategic metrics — rather than a straight commission rate on units sold, partly because reps influence prescribing rather than transact directly, and partly for regulatory reasons.
How much of a pharma rep’s pay is variable?
Typically 15–30% of total OTE across the European markets we looked at, compared with 35–50% for a comparable SaaS account executive. The exact share tends to rise for reps closer to launch-product or specialist roles, where activity and new-patient-start metrics carry more weight.
Does a company car count toward OTE?
No — the figures in this guide are cash OTE (base plus variable). A company car, fuel/travel allowance, and pension are separate benefits that make up a meaningful part of total reward in most European pharma sales roles, particularly in the UK, Germany, and France, but they’re not included in the ranges above.
How often should pharma incentive plans be re-benchmarked?
Annually at minimum, and sooner if a product changes lifecycle stage (launch, peak, loss of exclusivity), a territory is redrawn, or you see attainment or turnover patterns that suggest the plan is out of step with the market — see the mid-cycle change guidance in our field-force incentive plan guide.
Sources: Glassdoor UK/DE/FR/ES, Indeed UK/FR/ES, ERI SalaryExpert, HelloWork, France Travail, ABPI, Michael Page Life Sciences, EPM Scientific European Rates Guide. Compiled September 2026; figures are gross annual and directional.
